News

Filter

Current filters:

None

Popular Filters

1 to 25 of 8818 results

US FDA approves Gilead’s Zydelig for three types of blood cancers

24-07-2014

The US Food and Drug Administration late yesterday approved Zydelig (idelalisib), a new drug from US…

BiotechnologyGilead SciencesidelalisibOncologyRegulationUSAZydelig

GlaxoSmithKline slashes forecast as 2nd-qtr sales and earnings fall sharply

GlaxoSmithKline slashes forecast as 2nd-qtr sales and earnings fall sharply

23-07-2014

UK pharma giant GlaxoSmithKline saw its shares fall 3.9% to £45.94 shortly after the company reported…

FinancialFluticasone propionateGlaxoSmithKlinePharmaceuticalPulmonologyUK

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

23-07-2014

Shares of US biotech firm Biogen Idec jumped 7.35% to $326 in pre-market trading today, as the company…

AlprolixBiogen IdecBiotechnologyElocateFinancialImmunologyPharmacologyTecfideraUSA

Expert View: Has UK pharma lost its Euro-vision?

Expert View: Has UK pharma lost its Euro-vision?

23-07-2014

Former AstraZeneca serialization expert, Christoph Krähenbühl, demystifies the arguments around compliance…

EuropeEuropean UnionMarkets & MarketingMedicines verification infrastructurePharmaceuticalResearchUK

Shire in strategic collaboration with ArmaGen for Hunter syndrome

Shire in strategic collaboration with ArmaGen for Hunter syndrome

23-07-2014

Ireland-headquartered drugmaker Shire has entered into an agreement with US privately held biotech company…

AGT-182ArmagenBiotechnologyCNS DiseasesHunter syndromeIrelandLicensingShireUSA

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

Biotron’s BIT225 reverses HIV-induced impairment of the immune system

23-07-2014

Australian viral disease specialist Biotron presented data at the 20th International AIDS Conference,…

Anti-viralsAntiretroviral drugAustraliaBiotechnologyBiotronBIT225HIVHIV/AIDSImmune systemResearch

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

23-07-2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has…

Acute coronary syndromesCardio-vascularEfientEli LillyPharmaceuticalprasugrelRegulationUK

NICE recommends Amitiza to treat long-term, painful constipation

NICE recommends Amitiza to treat long-term, painful constipation

23-07-2014

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Amitiza (lubiprostone)…

AmitizaGastro-intestinalsGastroenterologyPharmaceuticalRegulationSucampoUK

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

23-07-2014

The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending…

Astellas PharmaBristol-Myers SquibbOncologyPharmaceuticalRegulationUKXtandiYervoy

Merck strengthens commitment to Chinese growth market

Merck strengthens commitment to Chinese growth market

23-07-2014

Germany’s Merck KGaA, a leading company for high-tech products in the pharmaceutical and chemical sectors,…

ChinaFinancialMerckMerck KGaAPharmaceuticalProductionResearch

South Africa’s NAPM calls for elimination of VAT on medicines

22-07-2014

South African trade group the National Association of Pharmaceutical Manufacturers (NAPM) has proposed…

FinancialGenericsNational Association of Pharmaceutical ManufacturersPoliticsPricingSouth Africa

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

Novasep sites approved by US FDA

Novasep sites approved by US FDA

22-07-2014

French active ngredients company Novasep has successfully completed US Food and Drug Administration pre-approval…

Active pharmaceutical ingredientFranceNovasepPharmaceuticalRegulationUSA

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

22-07-2014

Anglo-Swedish drug major AstraZeneca says that its global biologics research and development arm MedImmune…

AdvaxisADXS-HPVAstraZenecaBiotechnologyMedImmuneOncologyPapillomavirusResearchSweden

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

22-07-2014

Australian biotech company Regeneus has expanded its portfolio to include licensing of global rights…

AustraliaBiotechnologyFinancialOncologyOsteosarcomaRegeneusResearchSarcoma

1 to 25 of 8818 results

Back to top